Inactive Instrument

RenovaCare Inc Stock OTC Bulletin Board

US75988J1060

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

22-11-18	RenovaCare, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-08-12	RenovaCare, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI

RenovaCare, Inc. is a clinical-stage biotechnology company. The Company is focused on developing autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company through its wholly owned subsidiary, RenovaCare Sciences Corp. is focusing on the research, development and commercialization of autologous (using a patientâ€™s own cells) cellular therapies that can be used for medical and aesthetic applications. The Companyâ€™s CellMist System is a cell isolation procedure that enzymatically renders stem cells from the patientâ€™s own skin or other tissues. The resulting stem cell suspension is administered topically from the Companyâ€™s novel solution sprayer device (the SkinGun) as a cell therapy for wounds including burns to facilitate healing. Its SkinGun spray device is an advanced technology, using a gentle positive-pressure air stream to spray the CellMist Solution onto wounds.

Employees

Sector

Biotechnology & Medical Research

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	1.76M 1.52M 1.44M 1.31M 2.45M 168M 2.46M 17.17M 6.63M 85.43M 6.6M 6.45M 272M	P/E 2020	-25.6x	P/E 2021	-5.46x
Enterprise Value	-1.06M -921K -871K -790K -1.48M -102M -1.49M -10.39M -4.02M -51.72M -3.99M -3.9M -165M	EV / Sales 2020	-	EV / Sales 2021	-
Free-Float	100%	Yield 2020 *	-	Yield 2021	-

22-11-18	RenovaCare, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-08-12	RenovaCare, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
22-05-12	RenovaCare, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
22-05-03	RenovaCare Announces Termination of StemCell Systems R&D Agreement	CI
22-03-30	RenovaCare, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
22-03-29	RenovaCare, Inc. Auditor Raises 'Going Concern' Doubt	CI
22-03-24	RenovaCare, Inc. Announces Management Changes	CI
22-03-24	RenovaCare, Inc. Announces CFO Changes	CI
22-03-24	RenovaCare, Inc. Announces CEO Changes	CI
22-02-03	RenovaCare, Inc. Enters into A Research and Collaboration Agreement with Histocell, S.L	CI
21-11-12	RenovaCare, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
21-08-03	Renovacare, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	CI
21-07-22	RenovaCare, Inc Provides Update on Clinical Trial for the SkinGun™ and CellMist™ System for Wound Healing	CI

25-02-12	RenovaCare Inc. Provides Notice of Proposed Derivative Settlement to All Record Holders and Beneficial Owners of RenovaCare, Inc.	BU
22-11-18	RenovaCare: Q3 Earnings Snapshot	AQ
22-11-18	RENOVACARE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
22-08-12	RenovaCare: Q2 Earnings Snapshot	AQ
22-08-12	RENOVACARE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+0.66%	+0.87%	+47.39%	+97.63%	69.18B
ARGENX SE	-1.19%	-1.92%	+34.57%	+73.82%	62B
INSMED INCORPORATED	+2.23%	-4.34%	-14.88%	+364.07%	26.19B
WUXI BIOLOGICS (CAYMAN) INC.	+1.46%	+1.30%	+28.58%	+13.76%	25.75B
BIONTECH SE	-1.22%	-2.56%	-3.67%	-12.31%	24.29B
GENMAB A/S	+2.84%	+3.61%	+24.60%	-15.06%	19.84B
PHARMAESSENTIA CORPORATION	0.00%	-14.23%	+170.04%	+298.75%	15.65B
SUMMIT THERAPEUTICS INC.	-0.46%	-1.00%	-4.17%	+859.39%	13.88B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.39%	-5.61%	-9.51%	+483.04%	14.09B
Average	+0.43%	-1.90%	+30.33%	+240.34%	30.1B
Weighted average by Cap.	+0.30%	-0.98%	+31.89%	+162.56%

	2020	2021
Net sales	-	-
Net income	-9.55M -8.27M -7.82M -7.1M -13.31M -916M -13.39M -93.37M -36.08M -465M -35.87M -35.07M -1.48B	-4.47M -3.88M -3.66M -3.33M -6.23M -429M -6.27M -43.73M -16.9M -218M -16.8M -16.43M -694M
Net Debt	-7.33M -6.35M -6.01M -5.45M -10.22M -703M -10.28M -71.71M -27.71M -357M -27.55M -26.94M -1.14B	-2.82M -2.44M -2.31M -2.1M -3.93M -270M -3.95M -27.56M -10.65M -137M -10.59M -10.35M -437M

RenovaCare Inc Stock OTC Bulletin Board

Stocks

US75988J1060

Biotechnology & Medical Research

Valuation: RenovaCare Inc

Latest news: RenovaCare Inc

Press Releases: RenovaCare Inc

Managers and Directors: RenovaCare Inc

Bio Therapeutic Drugs

Financials

Company Profile